Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies.

Ritchie MD, Motsinger AA

Vanderbilt University Medical Center, Department of Molecular Physiology & Biophysics, 519 Light Hall, Center for Human Genetics Research, Nashville, TN 37232-0700, USA. ritchie@chgr.mc.vanderbilt.edu

In the quest for discovering disease susceptibility genes, the reality of gene-gene and gene-environment interactions creates difficult challenges for many current statistical approaches. In an attempt to overcome limitations with current disease gene detection methods, the multifactor dimensionality reduction (MDR) approach was previously developed. In brief, MDR is a method that reduces the dimensionality of multilocus information to identify polymorphisms associated with an increased risk of disease. This approach takes multilocus genotypes and develops a model for defining disease risk by pooling high-risk genotype combinations into one group and low-risk combinations into another. Cross-validation and permutation testing are used to identify optimal models. While this approach was initially developed for studies of complex disease, it is also directly applicable to pharmacogenomic studies where the outcome variable is drug treatment response/nonresponse or toxicity/no toxicity. MDR is a nonparametric and model-free approach that has been shown to have reasonable power to detect epistasis in both theoretical and empirical studies. This computational technology is described in detail in this review, and its application in pharmacogenomic studies is demonstrated.

Published 21 November 2005 in Pharmacogenomics, 6(8): 823-34.
Full-text of this article is available online (may require subscription).

© 2005-2008 Pharmacology Research Today. All Rights Reserved.